+ Include: 13 videos + 1 PDF, size: 8.78 GB
+ Target Audience: oncologists, hematologists
+ Information:
Treating patients without fully understanding the established and emerging molecular biomarkers for cancer outcomes can limit many aspects of patient care. Several approved biomarkers can now help predict prognosis, select appropriate therapy and/or define eligibility for clinical trials, and monitor for cancer recurrence. The WIN Symposium will provide attendees with a deep understanding of the role of such biomarkers, their optimal application, and emerging new omic tests that will inform future biomarker adoption under the two big umbrellas of Precision Genomics and Precision Immunotherapy. Local experience from the UAE, the host country, will also be included to link global evidence to regional practice. The application of the principles of precision medicine will also be discussed beyond medical and into radiation oncology. The symposium will also feature a Molecular Tumor Board to exemplify with real patient cases how to use biomarkers to inform therapeutic choices. Finally, a panel discussion will be dedicated to navigating available diagnostic pathways and tests from bench to bedside. We hope you find this meeting educational and practice-changing
Worldwide Innovative Network (WIN) Consortium is a non-profit association headquartered in France. The WIN network assembles 27 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations, and patient advocates spanning 18 countries and 5 continents, aligned to launch trials using its genomics and
transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology. WIN was started by the late John Mendelsohn, President of MD Anderson Cancer Center, U.S., and Thomas Tursz, Director General of Gustave Roussy, France. The consortium has since then been led by Richard L. Schilsky, Chair Emeritus of WIN, Former Executive Vice-President & Chief Medical Officer ASCO (2013-2021,) and Professor Emeritus at the University of Chicago, and Josep Tabernero, Vice-Chair of WIN, Head of Vall d’Hebron Institute of Oncology, Spain, and Past-President ESMO. Most recently, Wafik El-Deiry, American Cancer Society Research Professor, Director of Legoretta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, has been elected as Chair of WIN Consortium
Target Audience
The target audience spans a wide range of high-profile stakeholders in clinical and non-clinical cancer research, technology development, and patient management who are interested in furthering their understanding of the role of biomarkers in cancer management. These could include:
• Medical Oncologists
• Hematologists
• Surgical Oncologists
• Radiation Oncologists
• Pathologists
• Laboratory Medicine Specialists
• Pharmacists
• Nurses
• Clinical, Translational, and Basic Science Cancer Researchers
• Government officials involved in Cancer Care and Control
• Industry officials involved in Research and Development
+ Topics:
Mar 1 AstraZeneca Symposium.mp4
Mar 1 Keynote Lecture – Immune Checkpoint Blockade in Cancer Therapy.mp4
Mar 1 Novartis Symposium.mp4
Mar 1 Opening Ceremony.mp4
Mar 1 Session 1 Grand Opening.mp4
Mar 1 Session 2 – Precision Genomics – From Bench to Bedside.mp4
Mar 1 Session 3 – Precision Immunotherapy – The Next 5 Years.mp4
Mar 1 Session 4 – Precision Research.mp4
Mar 2 Hikma – Guardant Health Symposium.mp4
Mar 2 Session 5 – Molecular Tumor Board.mp4
Mar 2 Session 6 – Radiation Oncology in Precision Medicine.mp4
Mar 2 Session 7 – Precision Communityomics.mp4
Mar 2 Session 8 – Precision Diagnostics.mp4
Win-Consortium-2024-Book-26.pdf
